Aptorum Group Ltd

HONG KONG, K3 · CIK 0001734005 · Biotech · Public

Drug discovery and development platform for therapeutic candidates targeting infectious diseases and oncology

aptorumgroup.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$1.6M
1 Form D · May 2018
101 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,600,400
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1469Aptevo Therapeutics Inc.—$5.6M
1470Up Therapeutics LLC——
1471CALIFORNIA STEM CELL INC—$1.9M
1472Aptorum Group Ltd—$1.6M
1473RESBIOTIC, INC.—$1.6M
1474UBIVAC, INC.—$1.5M
1475EXSCIEN CORPORATION——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • Douglas ArnerDirector
  • Charles BathurstDirector
  • Keith ChanExecutive Officer
  • Clark ChengDirector
  • Ian HuenDirector · Executive Officer
  • Sabrina KhanExecutive Officer
  • Darren LuiDirector · Executive Officer
  • Mirko SchererDirector
  • Justin WuDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.